RxDoctor Payments Data

Beth Stevenson, NP

Family · Grand Rapids, MINPI 1225464555

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 86 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$478
  • Axsome Therapeutics, Inc.$148
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
  • W. L. Gore & Associates, Inc.$122
  • Corium, LLC$74
  • Alkermes, Inc.$69
  • plus $289 from 10 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 75th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$12,094
Medicare patients
90
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole44$60,696
Austedo XrDeutetrabenazine11$59,149
VraylarCariprazine Hcl31$47,242
SpravatoEsketamine Hcl11$24,412
Lisdexamfetamine Dimesylate19$4,453
Duloxetine Hcl51$3,735
Bupropion XlBupropion Hcl67$3,277
Vilazodone Hcl23$2,074
Divalproex Sodium29$1,522
Venlafaxine Hcl ErVenlafaxine Hcl43$1,219
Aripiprazole20$1,134
Trazodone Hcl107$958
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$891
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$780
Mirtazapine57$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$53$60,69644 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$35$59,14911 claims
AbbVieVraylar$478$47,24231 claims
Johnson & JohnsonSpravato$26$24,41211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,657 family providers in Michigan.

Other family in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →